Breast cancer Cancer Malignant neoplasm of breast
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Phase one: 1. Diagnosed with primary breast cancer 2. Prescribed hormonal therapy within the last three years Phase two: 1. =23 on the MARS 2. Has weekly access to smartphone or tablet 3. Has email address
Exclusion criteria
Exclusion criteria: 1. Diagnosed with secondary or metastatic cancer 2. Prescribed duration of hormonal therapy is due to come to an end during trial 3. Current treatment for depression or psychiatric disorders 4. Not fluent in verbal and written English Phase two: 1. Diagnosed with secondary or metastatic cancer 2. Prescribed duration of hormonal therapy is due to come to an end during trial 3. Current treatment for depression or psychiatric disorders 4. Not fluent in verbal and written English 5. Patient does not provide consent or refuses to be randomised 6. Patient is currently taking part in another trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adherence, measured using the MARS. Women be classified as adherent or non-adherent based on their scores on the MARS; Timepoint(s): baseline, 9 weeks, 6 months and 12 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Beliefs about hormone therapy, measured using BMQ-AET 2. Illness perceptions, measured using IPQ-BCS 3. Distress, measured using PHQ2, GAD7 4. Quality of life, measured using FACT-B 5. Side effects, measured using BCPT Symptom checklist 6. Satisfaction with information about treatment measured using The Satisfaction with Information about Medicines Scale (SIMS) 7. Self-efficacy for managing symptoms measured using a modified version of a standard self-efficacy scale 8. Perceived behavioural control measured using 4 items from a Theory of Planned Behaviour questionnaire All measures are collected at baseline, 9 weeks, 6 months and 12 months | — |
Countries
United Kingdom